A Phase 2 interventional study of tisotumab vedotin in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer, sponsored by Seagen Inc.. Completed at 37 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.
Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 13th largest by enrollment, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 16th registered.
3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 11 · Phase 3 5
First in 2003; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 38 interventional studies. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
3 of the studies in Ovarian Neoplasms by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Ovarian Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).
The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week cycle (3Q4W) for patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has relapsed within 6 months of the completion of platinum-based treatment and determined to be platinum resistant. All patients must have PROC and be eligible for single agent chemotherapy.
The safety run-in period will evaluate the safety of a weekly schedule. The highest dose level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1, 8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified. Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is considered safe and tolerable in the safety run-in period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A and Part B only: Patients with PROC who have received 1 to 3 anticancer overall, including at least 1 line of therapy containing bevacizumab or biosimilar.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
28-day, 3 dose cycle
Drug: tisotumab vedotin
21-day, single dose cycle
Drug: tisotumab vedotin
28-day, 3 dose cycle
Drug: tisotumab vedotin
28-day, 3 dose cycle
Drug: tisotumab vedotin
Intravenous (IV) infusion
Also known as: TIVDAK
Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)
Incidence of dose-limiting toxicity (DLT) was evaluated in participants enrolled in the Safety Run-In, who were followed for protocol-defined DLT events up to 28 days after the first dose of tisotumab vedotin.
Time frame: Up to 28 days
Confirmed Objective Response Rate (ORR) (Part B)
Proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator
Time frame: Up to 9.7 months
Number of Participants With Adverse Events (AEs) (Part B)
An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
Time frame: Up to 23.0 months
Confirmed and Unconfirmed ORR (Part B)
Proportion of participants who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator
Time frame: Up to 9.7 months
Cancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B)
Percentage of participants who have at least a 50% reduction in CA-125 value from baseline
Time frame: Up to 10.1 months
Overall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B)
Percentage of participants whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria
Time frame: Up to 10.1 months
Duration of Response (DOR) (Part B)
Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first
Time frame: Up to 8.3 months
Disease Control Rate (DCR) (Part B)
Percentage of participants who achieved a confirmed Complete Response(CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator, or meet the Stable Disease (SD) criteria at least once after start of study treatment at a minimum interval of 12 weeks.
Time frame: Up to 3.0 months
Time to Response (TTR) (Part B)
Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)
Time frame: Up to 23.0 months
Progression-free Survival (PFS) (Part B)
Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first
Time frame: Up to 9.7 months
Overall Survival (OS) (Part B)
Time from the start of study treatment to date of death due to any cause
Time frame: Up to 23.0 months
Incidence of Antitherapeutic Antibodies (ATA) (Part B)
The proportion of participants who develop ATA at any time during the study. A positive baseline ATA result is considered positive post-baseline if the post-baseline ATA titer result is at least four times higher than the baseline result.
Time frame: Up to 6.9 months
Pharmacokinetic (PK) Parameter: Antibody-Drug Conjugate (ADC) Maximum Concentration (Cmax) (Part B)
ADC Cmax was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: ADC Time of Cmax (Tmax) (Part B)
ADC Tmax was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: ADC Area Under Concentration-Time Curve (AUC) (Part B)
ADC AUC was derived from the PK blood samples collected.
Time frame: Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose).
PK Parameter: Free Monomethyl Auristatin E (MMAE) Cmax (Part B)
MMAE Cmax was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: MMAE Tmax (Part B)
MMAE Tmax was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: MMAE AUC (Part B)
MMAE AUC was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: MMAE Trough Concentration (Ctrough) (Part B)
MMAE Ctrough was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: Total Antibody (TAb) Cmax (Part B)
TAb Cmax was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: TAb Tmax (Part B)
TAb Tmax was derived from the PK blood samples collected.
Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
PK Parameter: TAb Area Under Concentration-Time Curve (AUC) (Part B)
TAb AUC was derived from the PK blood samples collected.
Time frame: Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose).
A total of 98 participants were enrolled into the Safety Run-In and Part B Expansion cohorts, of which 94 received study drug. No participants were enrolled into Part A.
| Milestone | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part A Q3W | Part A 3Q4W | Part B Expansion |
|---|---|---|---|---|---|
| Started | 8 | 8 | 0 | 0 | 82 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 8 | 0 | 0 | 82 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 4 |
| Withdrew: Study closure by sponsor | 0 | 2 | 0 | 0 | 17 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Death | 6 | 5 | 0 | 0 | 53 |
| Withdrew: Met exclusion criteria after enrollment | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal - subsequent treatment | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal - declined follow-up | 0 | 0 | 0 | 0 | 1 |
Incidence of dose-limiting toxicity (DLT) was evaluated in participants enrolled in the Safety Run-In, who were followed for protocol-defined DLT events up to 28 days after the first dose of tisotumab vedotin.
| Participants | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only) | 0 | 1 |
Proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator
| Participants | Part B Expansion |
|---|---|
| Confirmed Objective Response Rate (ORR) (Part B) | 7 |
An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
| Participants | Part B Expansion |
|---|---|
| Any TEAE | 79 |
| Treatment-related TEAE | 67 |
| Treatment-related Grade 3-4 TEAE | 14 |
| Treatment-related Grade 5 TEAE | 0 |
| Max severity of TEAE - Grade 1 | 7 |
| Max severity of TEAE - Grade 2 | 35 |
| Max severity of TEAE - Grade 3 | 32 |
| Max severity of TEAE - Grade 4 | 3 |
| Max severity of TEAE - Grade 5 | 2 |
| Any treatment-emergent serious AE (SAE) | 28 |
| Treatment-related SAE | 6 |
Proportion of participants who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator
| Percentage of Participants | Part B Expansion |
|---|---|
| Confirmed and Unconfirmed ORR (Part B) | 18.0 (10.0 to 27.9) |
Percentage of participants who have at least a 50% reduction in CA-125 value from baseline
| Percentage of Participants | Part B Expansion |
|---|---|
| Cancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B) | 12.0 (4.4 to 23.9) |
Percentage of participants whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria
| Percentage of Participants | Part B Expansion |
|---|---|
| Overall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B) | 11.0 (5.3 to 20.5) |
Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first
| Months | Part B Expansion |
|---|---|
| Duration of Response (DOR) (Part B) | 4.21 (3.02 to NA) |
Percentage of participants who achieved a confirmed Complete Response(CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator, or meet the Stable Disease (SD) criteria at least once after start of study treatment at a minimum interval of 12 weeks.
| Percentage of Participants | Part B Expansion |
|---|---|
| Disease Control Rate (DCR) (Part B) | 54.4 (42.8 to 65.7) |
Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)
| Months | Part B Expansion |
|---|---|
| Time to Response (TTR) (Part B) | 1.4 (1.0 to 3.0) |
Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first
| Months | Part B Expansion |
|---|---|
| Progression-free Survival (PFS) (Part B) | 2.73 (1.64 to 2.99) |
Time from the start of study treatment to date of death due to any cause
| Months | Part B Expansion |
|---|---|
| Overall Survival (OS) (Part B) | 10.68 (7.75 to 12.81) |
The proportion of participants who develop ATA at any time during the study. A positive baseline ATA result is considered positive post-baseline if the post-baseline ATA titer result is at least four times higher than the baseline result.
| Participants | Part B Expansion |
|---|---|
| Baseline Negative - Negative post-baseline | 65 |
| Baseline Negative - Positive post-baseline | 3 |
| Baseline Positive - Negative post-baseline | 3 |
| Baseline Positive - Positive post-baseline | 0 |
ADC Cmax was derived from the PK blood samples collected.
| µg/mL | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 | 20.582 ± 26.963 |
| Cycle 1, Dose 3 | 21.817 ± 26.823 |
ADC Tmax was derived from the PK blood samples collected.
| Days | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 | 0.041 ± 53.112 |
| Cycle 1, Dose 3 | 0.041 ± 78.407 |
ADC AUC was derived from the PK blood samples collected.
| µg/mL*day | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 - AUC 7 Days-ADC | 25.198 ± 25.335 |
| Cycle 1, Dose 3 - AUC 7 Days-ADC | 30.159 ± 32.261 |
| Cycle 1, Dose 3 - AUC 14 Days-ADC | 31.716 ± 31.632 |
MMAE Cmax was derived from the PK blood samples collected.
| ng/mL | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 | 1.778 ± 66.636 |
| Cycle 1, Dose 3 | 2.552 ± 52.442 |
MMAE Tmax was derived from the PK blood samples collected.
| Days | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 | 2.061 ± 26.838 |
| Cycle 1, Dose 3 | 2.101 ± 28.820 |
MMAE AUC was derived from the PK blood samples collected.
| ng/mL*day | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 - AUC Last-MMAE | 8.709 ± 63.747 |
| Cycle 1, Dose 3 - AUC Last-MMAE | 16.578 ± 52.121 |
MMAE Ctrough was derived from the PK blood samples collected.
| ng/mL | Part B Expansion |
|---|---|
| PK Parameter: MMAE Trough Concentration (Ctrough) (Part B) | 0.230 ± 82.638 |
TAb Cmax was derived from the PK blood samples collected.
| ng/mL | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 | 18.418 ± 28.631 |
| Cycle 1, Dose 3 | 19.955 ± 28.405 |
TAb Tmax was derived from the PK blood samples collected.
| Days | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 | 0.041 ± 67.072 |
| Cycle 1, Dose 3 | 0.043 ± 67.795 |
TAb AUC was derived from the PK blood samples collected.
| µg/mL*day | Part B Expansion |
|---|---|
| Cycle 1, Dose 1 - AUC 7 Days-TAb | 35.535 ± 24.950 |
| Cycle 1, Dose 3 - AUC 7 Days-TAb | 39.371 ± 29.218 |
| Cycle 1, Dose 3 - AUC 14 Days-TAb | 42.240 ± 29.206 |
Collected over Non-serious AEs were followed up to 10.5 months. Serious AEs and All-Cause Mortality were followed up to 31.6 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-In 0.9 mg/kg 3Q4W | 6/8 (75%) | 2/7 (28.6%) | 7/7 (100%) |
| Safety Run-In 1.2 mg/kg 3Q4W | 5/8 (62.5%) | 4/8 (50%) | 8/8 (100%) |
| Part B Expansion | 53/82 (64.6%) | 28/79 (35.4%) | 77/79 (97.5%) |
| Event | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/7 | 3/8 | 1/79 |
| AscitesGastrointestinal disorders | 1/7 | 0/8 | 1/79 |
| FatigueGeneral disorders | 1/7 | 1/8 | 0/79 |
| Performance status decreasedGeneral disorders | 1/7 | 0/8 | 0/79 |
| CellulitisInfections and infestations | 1/7 | 0/8 | 0/79 |
| Decreased appetiteMetabolism and nutrition disorders | 1/7 | 0/8 | 0/79 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 4/79 |
| Abdominal painGastrointestinal disorders | 0/7 | 1/8 | 2/79 |
| VomitingGastrointestinal disorders | 0/7 | 1/8 | 2/79 |
| Confusional statePsychiatric disorders | 0/7 | 1/8 | 0/79 |
| Event | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/7 | 0/8 | 23/79 |
| DiarrhoeaGastrointestinal disorders | 4/7 | 2/8 | 18/79 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/7 | 3/8 | 36/79 |
| FatigueGeneral disorders | 2/7 | 4/8 | 25/79 |
| Peripheral sensory neuropathyNervous system disorders | 3/7 | 2/8 | 18/79 |
| NauseaGastrointestinal disorders | 2/7 | 2/8 | 30/79 |
| Abdominal painGastrointestinal disorders | 0/7 | 3/8 | 22/79 |
| ConstipationGastrointestinal disorders | 2/7 | 3/8 | 17/79 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/7 | 3/8 | 9/79 |
| ConjunctivitisInfections and infestations | 2/7 | 1/8 | 25/79 |
The Safety Analysis Set includes all participants who received any amount of study drug.
| Age, Continuous(Years) | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion | Total |
|---|---|---|---|---|
| Median | 69.0 (50.0 to 87.0) | 67.5 (51.0 to 74.0) | 60.0 (38.0 to 81.0) | 62.0 (38.0 to 87.0) |
| Sex/Gender, Customized(Participants) | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion | Total |
|---|---|---|---|---|
| Female | 7 | 8 | 79 | 94 |
| Intersex | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 6 | 7 |
| White | 6 | 6 | 69 | 81 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion | Total |
|---|---|---|---|---|
| Hispanic or Latino/a, or of Spanish Origin | 0 | 1 | 9 | 10 |
| Not of Hispanic or Latino/a, or of Spanish Origin | 6 | 7 | 69 | 82 |
| Unknown | 1 | 0 | 1 | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Score(Participants) | Safety Run-In 0.9 mg/kg 3Q4W | Safety Run-In 1.2 mg/kg 3Q4W | Part B Expansion | Total |
|---|---|---|---|---|
| Grade 0 | 4 | 5 | 48 | 57 |
| Grade 1 | 3 | 3 | 31 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in Feb 2022, 34 months.
Results were first posted in May 2023, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 34 months is close to that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tisotumab vedotin